ArticleOncology letters2017

Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Haiyang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.